Inicio
Información del autor
Autor Andrés Felipe Escobar González
Comentario :
Médico Pediatra Hematólogo, Hospital Pablo Tobón Uribe.
|
Documentos disponibles escritos por este autor (11)
Clasificado(s) por (Año de edición descendente) Refinar búsqueda¿Es COVID-19 una enfermedad que afecta la médula ósea? Experiencia en donantes sanos de células hematopoyéticas en un centro de trasplante / Ángela María Tirado Giraldo ; Andrés Felipe Escobar González
Título : ¿Es COVID-19 una enfermedad que afecta la médula ósea? Experiencia en donantes sanos de células hematopoyéticas en un centro de trasplante Otros títulos : ¿Is COVID-19 a disease that affects the bone marrow? Experience in healthy donors of hematopoietic cells in a transplant center Tipo de documento : documento electrónico Autores : Ángela María Tirado Giraldo, ; Andrés Felipe Escobar González, Fecha de publicación : 2022 Títulos uniformes : Revista Pediatría Idioma : Español (spa) Palabras clave : COVID-19 Infección Hematología Médula ósea Trasplante Resumen : Objetivo: escribir y analizar el efecto de la infección por el virus SARS-CoV-2 sobre la movilización de células en donantes de precursores hematopoyéticos que acudieron a la unidad de trasplante de precursores hematopoyéticos de una institución médica de alta complejidad en Medellín, Colombia. Métodos: estudio transversal retrospectivo analítico basado en registros médicos de pacientes sometidos a trasplante de médula ósea en una entre marzo de 2020 y marzo de 2021.Resultados: de 64 donantes y receptores de células hematopoyéticas, el 22.2 % de los receptores con antecedentes positivos de infección del donante tuvieron fracaso del injerto de granulocitos en comparación con el 9.1 % de los receptores sin estos antecedentes; no hubo diferencia en la tasa de mortalidad. La mediana de células CD34 movilizadas en población donante con antecedente de infección fue de 5 437 965 [RIC 5 070 714 – 7 215 985], similar a los donantes sin antecedente (Mediana de 5 976 773 [RIC 5 046 689 – 7 276 463]) sin encontrar diferencias (p=0.28).Conclusiones: no es posible determinar que la infección por SARS-CoV-2 genere cambios en las células que se movilizan de un donante de células madre hematopoyéticas por lo demás sano, con base en el análisis estadístico que realizamos, no creemos que los datos varíen si se amplía la población estudio, sin embargo se requieren más estudios prospectivos en el futuro. Mención de responsabilidad : Sara Isabel Noreña Gómez, Angie Carolina Morales Suárez, Ángela María Tirado Giraldo, Andrés Felipe Escobar González DOI (Digital Object Identifier) : 10.14295/rp.v55i4.399 Derechos de uso : CC BY-NC-ND En línea : https://revistapediatria.org/rp/article/view/399 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=6122 ¿Es COVID-19 una enfermedad que afecta la médula ósea? Experiencia en donantes sanos de células hematopoyéticas en un centro de trasplante = ¿Is COVID-19 a disease that affects the bone marrow? Experience in healthy donors of hematopoietic cells in a transplant center [documento electrónico] / Ángela María Tirado Giraldo, ; Andrés Felipe Escobar González, . - 2022.
Obra : Revista Pediatría
Idioma : Español (spa)
Palabras clave : COVID-19 Infección Hematología Médula ósea Trasplante Resumen : Objetivo: escribir y analizar el efecto de la infección por el virus SARS-CoV-2 sobre la movilización de células en donantes de precursores hematopoyéticos que acudieron a la unidad de trasplante de precursores hematopoyéticos de una institución médica de alta complejidad en Medellín, Colombia. Métodos: estudio transversal retrospectivo analítico basado en registros médicos de pacientes sometidos a trasplante de médula ósea en una entre marzo de 2020 y marzo de 2021.Resultados: de 64 donantes y receptores de células hematopoyéticas, el 22.2 % de los receptores con antecedentes positivos de infección del donante tuvieron fracaso del injerto de granulocitos en comparación con el 9.1 % de los receptores sin estos antecedentes; no hubo diferencia en la tasa de mortalidad. La mediana de células CD34 movilizadas en población donante con antecedente de infección fue de 5 437 965 [RIC 5 070 714 – 7 215 985], similar a los donantes sin antecedente (Mediana de 5 976 773 [RIC 5 046 689 – 7 276 463]) sin encontrar diferencias (p=0.28).Conclusiones: no es posible determinar que la infección por SARS-CoV-2 genere cambios en las células que se movilizan de un donante de células madre hematopoyéticas por lo demás sano, con base en el análisis estadístico que realizamos, no creemos que los datos varíen si se amplía la población estudio, sin embargo se requieren más estudios prospectivos en el futuro. Mención de responsabilidad : Sara Isabel Noreña Gómez, Angie Carolina Morales Suárez, Ángela María Tirado Giraldo, Andrés Felipe Escobar González DOI (Digital Object Identifier) : 10.14295/rp.v55i4.399 Derechos de uso : CC BY-NC-ND En línea : https://revistapediatria.org/rp/article/view/399 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=6122 Reserva
Reservar este documentoEjemplares(1)
Código de barras Número de Ubicación Tipo de medio Ubicación Sección Estado DD001989 AC-2022-128 Archivo digital Producción Científica Artículos científicos Disponible Documentos electrónicos
AC-2022-128Adobe Acrobat PDF
Título : Haploidentical stem cell transplant with post-transplant cyclophosphamide in pediatric hemophagocytic lymphohistiocytosis Tipo de documento : documento electrónico Autores : Luz Natalia Builes Restrepo, ; Andrés Felipe Escobar González, Fecha de publicación : 2021 Títulos uniformes : Journal of Clinical Immunology Idioma : Inglés (eng) Palabras clave : Hemophagocytic lymphohistiocytosis hematopoietic stem cell transplantation child cyclophosphamide haploidentical Resumen : Purpose: Primary hemophagocytic lymphohistiocytosis is a severe and uncommon disease affecting pediatric patients. Genetic abnormalities have been related to altered apoptosis and exaggerated inflammatory reactions. Chemoimmunotherapy and stem cell transplantation are treatment options, but transplant is the only curative treatment. Here we aim to describe the treatment with hematopoietic stem cell transplantation with a novel strategy and the outcomes. Methods: An observational, descriptive, case series study was performed in pediatric patients of two high complexity medical centers in Colombia. Data was collected retrospectively between 2015 and 2020. Results: We describe five pediatric cases with a diagnosis of primary hemophagocytic lymphohistiocytosis. All were treated with replete-cell haploidentical hematopoietic stem transplantation, reduced-intensity conditioning, and post-transplant cyclophosphamide, in two high-complexity centers in Colombia. All patients are alive, and one is receiving management for chronic graft-versus-host disease. Conclusion: To the best of our knowledge, there are few reports in the literature with this strategy, promising a possible alternative when there are no other donor options. Mención de responsabilidad : Diego Medina-Valencia, Daniela Cleves, Estefania Beltran, Natalia Builes, Alexis A. Franco, Andrés Felipe Escobar-González & Manuela Olaya Referencia : J Clin Immunol. 2021 Aug;41(6):1172-1177. DOI (Digital Object Identifier) : 10.1007/s10875-021-01009-3 PMID : 33687579 En línea : https://link.springer.com/article/10.1007%2Fs10875-021-01009-3 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=5762 Haploidentical stem cell transplant with post-transplant cyclophosphamide in pediatric hemophagocytic lymphohistiocytosis [documento electrónico] / Luz Natalia Builes Restrepo, ; Andrés Felipe Escobar González, . - 2021.
Obra : Journal of Clinical Immunology
Idioma : Inglés (eng)
Palabras clave : Hemophagocytic lymphohistiocytosis hematopoietic stem cell transplantation child cyclophosphamide haploidentical Resumen : Purpose: Primary hemophagocytic lymphohistiocytosis is a severe and uncommon disease affecting pediatric patients. Genetic abnormalities have been related to altered apoptosis and exaggerated inflammatory reactions. Chemoimmunotherapy and stem cell transplantation are treatment options, but transplant is the only curative treatment. Here we aim to describe the treatment with hematopoietic stem cell transplantation with a novel strategy and the outcomes. Methods: An observational, descriptive, case series study was performed in pediatric patients of two high complexity medical centers in Colombia. Data was collected retrospectively between 2015 and 2020. Results: We describe five pediatric cases with a diagnosis of primary hemophagocytic lymphohistiocytosis. All were treated with replete-cell haploidentical hematopoietic stem transplantation, reduced-intensity conditioning, and post-transplant cyclophosphamide, in two high-complexity centers in Colombia. All patients are alive, and one is receiving management for chronic graft-versus-host disease. Conclusion: To the best of our knowledge, there are few reports in the literature with this strategy, promising a possible alternative when there are no other donor options. Mención de responsabilidad : Diego Medina-Valencia, Daniela Cleves, Estefania Beltran, Natalia Builes, Alexis A. Franco, Andrés Felipe Escobar-González & Manuela Olaya Referencia : J Clin Immunol. 2021 Aug;41(6):1172-1177. DOI (Digital Object Identifier) : 10.1007/s10875-021-01009-3 PMID : 33687579 En línea : https://link.springer.com/article/10.1007%2Fs10875-021-01009-3 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=5762 Reserva
Reservar este documentoEjemplares(1)
Código de barras Número de Ubicación Tipo de medio Ubicación Sección Estado DD001687 AC-2021-013 Archivo digital Producción Científica Artículos científicos Disponible
Título : Meta-analysis of hematopoietic stem cell transplantation in major histocompatibility complex class II deficiency Tipo de documento : documento electrónico Autores : Andrés Felipe Escobar González, Fecha de publicación : 2020 Títulos uniformes : Pediatric Transplantation Idioma : Inglés (eng) Palabras clave : hematopoietic stem cell transplant major histocompatibility complex class II deficiency primary immunodeficiency Resumen : Major histocompatibility complex class II deficiency is a rare case of PID. Specific recommendations for hematopoietic stem cell transplant, the only curative treatment option, are still lacking. This meta‐analysis aims to identify the factors associated with better prognosis in these patients. Thirteen articles reporting 63 patients with major histocompatibility complex class II deficiency that underwent hematopoietic stem cell transplant were included. The median age for hematopoietic stem cell transplant was 18 months. The most common source of transplant was bone marrow, with alternative sources as umbilical cord blood emerging during recent years. The highest proportion of engraftment was seen with umbilical cord. Engraftment was higher in patients with matched donors, with better overall survival in patients with reduced‐intensity conditioning. Graft‐vs‐host disease developed in 65% of the patients, with grades I‐II being the most frequently encountered. There was a higher mortality in patients with myeloablative conditioning and no engraftment. There was an inverse correlation between survival and stage of graft‐vs‐host disease. The main cause of mortality was infectious disease, mostly secondary to viral infections. Ideally, matched grafts should be used, and reduced‐intensity conditioning should be considered to reduce early post‐transplant complications. GVHD and viral prophylaxis are fundamental. Mención de responsabilidad : Lina Maria Castano‐Jaramillo, Jose Bareño‐Silva, Santiago Tobon, Andres Felipe Escobar‐Gonzalez Referencia : Pediatr Transplant. 2020 Sep;24(6):e13774. DOI (Digital Object Identifier) : 10.1111/petr.13774 PMID : 32678504 En línea : https://onlinelibrary.wiley.com/doi/abs/10.1111/petr.13774 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=5138 Meta-analysis of hematopoietic stem cell transplantation in major histocompatibility complex class II deficiency [documento electrónico] / Andrés Felipe Escobar González, . - 2020.
Obra : Pediatric Transplantation
Idioma : Inglés (eng)
Palabras clave : hematopoietic stem cell transplant major histocompatibility complex class II deficiency primary immunodeficiency Resumen : Major histocompatibility complex class II deficiency is a rare case of PID. Specific recommendations for hematopoietic stem cell transplant, the only curative treatment option, are still lacking. This meta‐analysis aims to identify the factors associated with better prognosis in these patients. Thirteen articles reporting 63 patients with major histocompatibility complex class II deficiency that underwent hematopoietic stem cell transplant were included. The median age for hematopoietic stem cell transplant was 18 months. The most common source of transplant was bone marrow, with alternative sources as umbilical cord blood emerging during recent years. The highest proportion of engraftment was seen with umbilical cord. Engraftment was higher in patients with matched donors, with better overall survival in patients with reduced‐intensity conditioning. Graft‐vs‐host disease developed in 65% of the patients, with grades I‐II being the most frequently encountered. There was a higher mortality in patients with myeloablative conditioning and no engraftment. There was an inverse correlation between survival and stage of graft‐vs‐host disease. The main cause of mortality was infectious disease, mostly secondary to viral infections. Ideally, matched grafts should be used, and reduced‐intensity conditioning should be considered to reduce early post‐transplant complications. GVHD and viral prophylaxis are fundamental. Mención de responsabilidad : Lina Maria Castano‐Jaramillo, Jose Bareño‐Silva, Santiago Tobon, Andres Felipe Escobar‐Gonzalez Referencia : Pediatr Transplant. 2020 Sep;24(6):e13774. DOI (Digital Object Identifier) : 10.1111/petr.13774 PMID : 32678504 En línea : https://onlinelibrary.wiley.com/doi/abs/10.1111/petr.13774 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=5138 Reserva
Reservar este documentoEjemplares(1)
Código de barras Número de Ubicación Tipo de medio Ubicación Sección Estado DD001398 AC-2020-075 Archivo digital Producción Científica Artículos científicos Disponible
Título : Ethylmalonic encephalopathy: a cause of petechiae without alteration in platelet or coagulation tests Tipo de documento : documento electrónico Autores : Andrés Felipe Escobar González, Fecha de publicación : 2019 Títulos uniformes : EC Paediatrics Idioma : Inglés (eng) Palabras clave : Ethylmalonic Encephalopathy Hydrogen Sulfide Ethylmalonic Aciduria Progressive Encephalopathy Petechia Acrocyanosis Resumen : Ethylmalonic encephalopathy (EE) is an autosomal recessive disease, rare, whose origin is given by mutations in the gene ETHE1, which codes for the protein of the same name and acts as a sulfur dioxygenase converting it into non-dangerous components such as thiosulfate and sulfate. The mutations generate an accumulation of hydrogen sulfide (H2S), which at high concentrations acts as an inhibitor of cytochrome c oxidase (COX) and acylCoA. Its main sites of accumulation are brain, liver, smooth muscle and colonic mucosa. The deficit of COX produces high levels of lactate in the blood and accumulation of ethylmalonic acid with the consequent excretion of the latter in urine (ethylmalonic aciduria) and, on the other hand, the decrease in short chain acylCoA dehydrogenase causes an increase in C4-C5 acylcarnitines. Biochemically, the disease is characterized by plasma lactate elevation, methylmalonic aciduria, altered levels of C4-C5 acylcarnitines, cytochrome c oxidase deficiency (COX) and increased thiosulfate concentration. Clinically, the affected systems are central nervous system (CNS), gastrointestinal and peripheral vessels, manifesting with neurological alterations characterized by progressive encephalopathy, chronic diarrhea, petechiae and acrocyanosis. The disease is of early onset, and in most patients the disease is severe with death occurring in the first years of life. So far there is no cure for the disease, but treatments that improve clinical manifestations and survival of patients, being useful N-acetylcysteine and metronidazole, which reduce H2S concentrations. Mención de responsabilidad : Andres Felipe Escobar González and Diana Carolina Vásquez Pino En línea : https://www.ecronicon.com/ecpe/pdf/ECPE-08-00447.pdf Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=4992 Ethylmalonic encephalopathy: a cause of petechiae without alteration in platelet or coagulation tests [documento electrónico] / Andrés Felipe Escobar González, . - 2019.
Obra : EC Paediatrics
Idioma : Inglés (eng)
Palabras clave : Ethylmalonic Encephalopathy Hydrogen Sulfide Ethylmalonic Aciduria Progressive Encephalopathy Petechia Acrocyanosis Resumen : Ethylmalonic encephalopathy (EE) is an autosomal recessive disease, rare, whose origin is given by mutations in the gene ETHE1, which codes for the protein of the same name and acts as a sulfur dioxygenase converting it into non-dangerous components such as thiosulfate and sulfate. The mutations generate an accumulation of hydrogen sulfide (H2S), which at high concentrations acts as an inhibitor of cytochrome c oxidase (COX) and acylCoA. Its main sites of accumulation are brain, liver, smooth muscle and colonic mucosa. The deficit of COX produces high levels of lactate in the blood and accumulation of ethylmalonic acid with the consequent excretion of the latter in urine (ethylmalonic aciduria) and, on the other hand, the decrease in short chain acylCoA dehydrogenase causes an increase in C4-C5 acylcarnitines. Biochemically, the disease is characterized by plasma lactate elevation, methylmalonic aciduria, altered levels of C4-C5 acylcarnitines, cytochrome c oxidase deficiency (COX) and increased thiosulfate concentration. Clinically, the affected systems are central nervous system (CNS), gastrointestinal and peripheral vessels, manifesting with neurological alterations characterized by progressive encephalopathy, chronic diarrhea, petechiae and acrocyanosis. The disease is of early onset, and in most patients the disease is severe with death occurring in the first years of life. So far there is no cure for the disease, but treatments that improve clinical manifestations and survival of patients, being useful N-acetylcysteine and metronidazole, which reduce H2S concentrations. Mención de responsabilidad : Andres Felipe Escobar González and Diana Carolina Vásquez Pino En línea : https://www.ecronicon.com/ecpe/pdf/ECPE-08-00447.pdf Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=4992 Reserva
Reservar este documentoEjemplares(1)
Código de barras Número de Ubicación Tipo de medio Ubicación Sección Estado DD001402 AC-2019-093 Archivo digital Producción Científica Artículos científicos Disponible
Título : Hemofilia: generalidades Tipo de documento : documento electrónico Autores : Andrés Felipe Escobar González, Fecha de publicación : 2019 Títulos uniformes : Programa de Educación Continua en Pediatría PRECOP Idioma : Español (spa) Mención de responsabilidad : Andres Felipe Escobar González, MD; Hendry Daniel Guao Salinas, MD En línea : https://issuu.com/precopscp/docs/24_5 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=4993 Hemofilia: generalidades [documento electrónico] / Andrés Felipe Escobar González, . - 2019.
Obra : Programa de Educación Continua en Pediatría PRECOP
Idioma : Español (spa)
Mención de responsabilidad : Andres Felipe Escobar González, MD; Hendry Daniel Guao Salinas, MD En línea : https://issuu.com/precopscp/docs/24_5 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=4993 Reserva
Reservar este documentoEjemplares(1)
Código de barras Número de Ubicación Tipo de medio Ubicación Sección Estado DD001546 AC-2019-094 Archivo digital Producción Científica Artículos científicos Disponible PermalinkPermalinkPermalinkPermalinkPermalinkGuía básica de hematología infantil
Permalink
